Results 191 to 200 of about 58,467 (222)

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines

Cancer Immunology, Immunotherapy, 2002
The tumour antigen ErbB-2 belongs to the epidermal growth factor receptor family. Numerous studies have shown that ErbB-2 is overexpressed in many cancers and it is prognostically important in a subset of malignancies. It is well recognised that this receptor has many characteristics that make it an excellent target for tumour-specific immunotherapy ...
Yip, Yum L., Ward, Robyn L.
openaire   +3 more sources

Inhibition of erbB-2-Positive Breast Cancer Cell Growth by erbB-2 Antisense Oligonucleotides

Antisense and Nucleic Acid Drug Development, 1996
Overexpression of erbB-2 proto-oncogene has been found in 20%-30% of human breast carcinomas and in most cases correlates with poor clinical prognosis. Using antisense oligonucleotides targeted to the 5' cap region of erbB-2RNA, we were able to inhibit erbB-2 protein expression, proliferation, and anchorage-independent growth of breast cancer cells up ...
X, Liu, B G, Pogo
openaire   +2 more sources

C-erbB-2 Immunostaining in Laryngeal Cancer

Acta Oto-Laryngologica, 1999
Tumour progression is strongly associated with a series of specific genetic changes in protooncogenes and tumour suppressor genes. One of the potential factors involved in tumorogenesis of squamous cell carcinomas is protooncogene c-erbB-2 (also known as neu or HER2). The authors analysed the expression of c-erbB-2 oncoprotein in 154 cases of laryngeal
T, Krecicki, M, Jeleń, M, Zalesska-Krecicka   +2 more
openaire   +2 more sources

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Bioorganic & Medicinal Chemistry Letters, 2009
Two new series of potent and selective dual EGFR/ErbB-2 kinase inhibitors derived from novel thienopyrimidine cores have been identified. Isomeric thienopyrimidine cores were evaluated as isosteres for a 4-anilinoquinazoline core and several analogs containing the thieno[3,2-d]pyrimidine core showed anti-proliferative activity with IC(50) values less ...
Tara R, Rheault, Thomas R, Caferro, Scott H, Dickerson, Kelly H, Donaldson, Michael D, Gaul, Aaron S, Goetz, Robert J, Mullin, Octerloney B, McDonald, Kimberly G, Petrov, David W, Rusnak, Lisa M, Shewchuk, Glenn M, Spehar, Anne T, Truesdale, Dana E, Vanderwall, Edgar R, Wood, David E, Uehling   +15 more
openaire   +2 more sources

Targeting low-expressing ERBB-2 and acquired resistant high-expressing ERBB-2 breast carcinomas.

Journal of Clinical Oncology, 2013
e11513 Background: Human epidermal growth factor receptors and their ligands are involved in carcinogenesis. Four ERBB receptors have been identified; ERBB1 (EB1), ERBB2 (EB2), ERBB3 (EB3) and ERBB4 (EB4). EB2 is over-expressed/amplified in 20-30% of BCa.
Michalis Karamouzis, Geena Dalagiorgou, Sonia A. Perez, Urania Georgopoulou, Athanasios Papavassiliou   +4 more
openaire   +1 more source

Surface distribution and internalization of erbB-2 Proteins

Experimental Cell Research, 1992
We report the localization over the cell surface and the early steps of antibody-induced internalization of the product of the erbB-2 proto-oncogene, structurally related to the epidermal growth factor receptor (EGFR). We show that erbB-2/p 185 is mostly excluded from endocytic pits on the cell surface.
LOTTI, Lavinia Vittoria, Claudia Di Lazzaro, ZOMPETTA, Claudia, FRATI, Luigi, TORRISI, Maria Rosaria   +4 more
openaire   +3 more sources

Neu/ErbB-2 Receptor

1995
Abstract The rodent 185 kD glycoprotein consists of 1260 amino acids (Bargmann et a/. 1986) (GenBank accession number X03662), whereas the human protein is 1255 amino acids long (Coussens eta/. 1985; Yamamoto et al. 1986) (GenBank accession number M11730).
Y Yarden, R B Levy
openaire   +1 more source

C‐ErbB‐2 Oncoprotein Immunostaining In Serous Effusions

Cytopathology, 1993
The product of c‐erbB‐2 gene is detected in a proportion of carcinomas from various sites and is generally associated with a high degree of malignancy. A series of 58 effusions containing malignant cells and 16 cytologically negative serous effusions was assessed by immunocyto‐chemical methods for c‐erbB‐2 expression using the monoclonal antibody NCL ...
ASCOLI, Valeria, C. C.A.R.N.O.V.A.L.E. SCALZO, F. NARDI   +2 more
openaire   +3 more sources

c-erbB-2 amplification in mammary carcinoma

Journal of Cellular Biochemistry, 1993
The c-erbB-2 oncogene has been extensively studied in mammary carcinomas since Slamon and colleagues demonstrated the association between amplification and poor prognosis in 1987. Further work found that amplification was accompanied by overexpression of the protein; however, this relationship is not perfect.
openaire   +2 more sources